Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces financial results for the three and six months ended June 30, 2015.
Highlights of the second quarter and recent weeks included:
- Quarterly product revenue of $0.5 million, an increase of nearly 85.7% compared with the second quarter of 2014
- Total operating expenses decreased by 35.1% to $4.0 million from $6.1 million in the second quarter of 2014
- Enrollment opened for an intrahepatic cholangiocarcinoma (ICC) cohort of the Company's global Phase 2 trial of Melphalan/HDS in hepatocellular carcinoma
- Positive data regarding the Delcath Hepatic CHEMOSAT® Delivery System highlighted at ASCO 2015
- Exceeded 200 commercial treatments performed with CHEMOSAT since the product was launched in Europe
- Multiple abstracts accepted for presentation at upcoming major medical conferences, including CIRSE, ESMO, and EADO
- Benefits of CHEMOSAT therapy to liver cancer patients affirmed by Key Opinion Leaders at European forum
- Jennifer Simpson, Ph.D., MSN, CRNP named President and CEO
- Granted U.S. Orphan Drug Designation for Melphalan/HDS for the treatment of cholangiocarcinoma from the U.S. Food and Drug Administration (FDA)
"We made considerable progress toward achieving our key milestones for 2015 as evidenced by continued revenue growth, increasing procedure volumes and advancement of our clinical development program," said Dr. Simpson. "We once again achieved record quarterly product revenue with year-over-year and sequential increases that have us already meeting our full-year 2014 sales on a local currency basis. This growth underscores our commercial progress in key European markets and highlights continued market adoption of CHEMOSAT.
"The opening of enrollment of the ICC cohort of our Phase 2 HCC study was a meaningful milestone as we believe our Melphalan/HDS treatment may offer significant clinical benefit for ICC patients who face limited treatment options. A positive efficacy signal may provide a regulatory path to a U.S. registration trial in this indication, and consolidated safety data from the HCC and ICC cohorts will offer valuable information for us to provide to the FDA. Our recent receipt of orphan drug designation from the FDA for melphalan for the treatment of cholangiocarcinoma, which includes ICC, highlights the medical need for viable treatments in this indication.
"We continue to advance our plans for a global pivotal Phase 3 clinical trial in ocular melanoma (OM) that has metastasized to the liver with overall survival as the primary endpoint. We hope to initiate this trial by the end of 2015.
"The positive feedback from the three-day Key Opinion Leader Forum we convened with leading clinicians from across Europe who are using CHEMOSAT was very encouraging. We look forward to these favorable findings being published in a white paper in a peer-reviewed journal.
"We are pleased with the meaningful progress made this quarter. With the additional resources secured through our recent public offering, we are well positioned to achieve several critical milestones during the second half of 2015," concluded Dr. Simpson.
Second Quarter Financial Results
Total revenue for the second quarter of 2015 of $0.5 million increased 85.7% from $0.3 million for the second quarter of 2014. Selling, general and administrative expenses during the second quarter of 2015 were $2.5 million, a decrease of $2.1 million or 45.6% from $4.6 million for the same period in 2014.
Total operating expenses for the second quarter of 2015 decreased by 35.1% to $4.0 million from $6.1 million for the same period in 2014. This decrease reflects a reduction in severance and compensation-related expenses following significant workforce restructurings throughout 2014 and into 2015, as well as a reduction in facility expenses following sub-leases of its 810 Seventh Ave location in 2014.
The Company recorded a net loss for the second quarter of 2015 of $3.7 million, a decrease of $0.9 million or 19.6%, compared with a net loss of $4.6 million for the same period in 2014. This decrease is primarily due to a $2.1 million reduction in operating expenses, a $0.1 million improvement in gross profit and a $1.3 million change in the fair value of the warrant liability, a non-cash item.
First Half Financial Result
Total revenue for the first half of 2015 of $0.9 million increased 62.2% from $0.6 million for the first half of 2014. Selling, general and administrative expenses during the first half of 2015 were $5.5 million, a decrease of $2.9 million or 34.1% from $8.4 million for the same period in 2014.
Total operating expenses for the first half of 2015 decreased by 29.9% to $8.0 million from $11.4 million for the same period in 2014. This decrease reflects a reduction in severance and compensation-related expenses following significant workforce restructurings throughout 2014 and into 2015, as well as a reduction in facility expenses following sub-leases of its 810 Seventh Ave location in 2014.
The Company recorded a net loss for the first half of 2015 of $7.2 million, a decrease of $2.7 million or 27.2% compared with a net loss of $9.9 million for the same period in 2014. This decrease is primarily due to a $3.4 million reduction in operating expenses, a $0.2 million improvement in gross profit and a $0.9 million change in the fair value of the warrant liability, a non-cash item.
Balance Sheet Highlights
Cash and cash equivalents as of June 30, 2015 were $14.1 million, compared with $20.5 million as of December 31, 2014. During the first six months of 2015, net cash used in operating activities was $9.0 million.
New vaccine shows potential in preventing recurrence of triple-negative breast cancer